IGC PHARMA, INC. Loss Contingency Accrual, Provision
IGC PHARMA, INC. (IGC) reported Loss Contingency Accrual, Provision of $1.90 million for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-23.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LossContingencyAccrualProvision · last filed 2022-06-23
- IGC PHARMA, INC. loss contingency accrual, provision for fiscal 2022 was $1.90M.
| Period end | Loss Contingency Accrual, Provision 12 month |
|---|---|
| 2022-03-31 | $1.90M 10-K · filed 2022-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |